STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer's disease world

Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the Alzheimer’s disease world is being exposed and will hopefully get cleaned up.

Remi Barbier, Cassava’s longtime CEO, has resigned and is also leaving the board, the company announced Wednesday. Lindsay Burns, Cassava’s senior vice president of neuroscience, is gone, too. She is married to Barbier.

Their abrupt departures come after the ​​Justice Department, on June 28, charged the company’s chief scientific collaborator and paid consultant, Hoau-Yan Wang, with multiple counts of fraud related to grants supporting Cassava’s experimental Alzheimer’s drug, called simufilam.

Continue to STAT+ to read the full story…

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!